US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Invion Limited (IVXO) 銘柄情報

Invion Limited (IVXO)

0.001

-0.001

(-50.00%)

終了 6月28日 3:00PM

Invion Limited (IVXO) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.001

( -50.00% )

買値

0.001

売値

0.003

出来高

200,000

0.001 日の範囲 0.001

0.001 52 週間の範囲 0.04

時価総額

前日終値

0.002

始値

0.001

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 195,771

発行済株式数

96,965,315

配当利回り

PER

-0.33

1 株当たり利益 (EPS)

-0.13

歳入

-

純利益

-10.5M

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-ge... Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.inviongroup.com

本社

Melbourne, Australia

設立

2026

Invion Limited is listed in the Healthcare sector of the オーストラリア証券取引所 with ticker IVXO. The last closing price for Invion was AUD0. Over the last year, Invion shares have traded in a share price range of AUD 0.001 to AUD 0.04.

Invion currently has 96,965,315 shares in issue. The market capitalisation of Invion is AUD96,965.32 . Invion has a price to earnings ratio (PE ratio) of -0.33.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0.001	0	0	0	DE
4	-0.001	-50	0.002	0.002	0.001	94749	0.002	DE
12	-0.012	-92.3076923077	0.013	0.013	0.001	263044	0.00519179	DE
26	-0.021	-95.4545454545	0.022	0.026	0.001	229431	0.0055514	DE
52	-0.024	-96	0.025	0.04	0.001	272504	0.02209665	DE
156	0	0	0.001	0.04	0.001	261381	0.02209665	DE
260	-0.002	-66.6666666667	0.003	0.04	0.001	2371089	0.0043122	DE

IVXO - Frequently Asked Questions (FAQ)

What is the current Invion Limited share price?

The current share price of Invion Limited is AUD 0.001

How many Invion Limited shares are in issue?

Invion Limited has 96,965,315 shares in issue

What is the market cap of Invion Limited?

The market capitalisation of Invion Limited is AUD 96.97k

What is the 1 year trading range for Invion Limited share price?

Invion Limited has traded in the range of AUD 0.001 to AUD 0.04 during the past year

What is the PE ratio of Invion Limited?

The price to earnings ratio of Invion Limited is -0.33

What is the registered address of Invion Limited?

The registered address for Invion Limited is 385 Bourke Street, Melbourne, Victoria, 3000

What is the Invion Limited website address?

The website address for Invion Limited is www.inviongroup.com

Which industry sector does Invion Limited operate in?

Invion Limited operates in the Pharmaceuticals sector

SC8

Except in the first released anecdote out of India, the treatment failed to kill tumor, just as it failed to kill 10 out of 12 treated rabbit tumors before that. There was a second set of rabbits, presumably treated at higher Radiogel doses, but RDGL buried those results. In short, there's never b

Myth

Here's an 8k from 2021, talking shite about an S1....

https://www.sec.gov/Archives/edgar/data/1069680/000149315221004946/ex1.htm

nwtf

How long will it take for you to start calling everyone short sellers like you did on the ERHE board.

Huggy Bear

Huggy Bear 3分前

AABB is 100% fraudulent garbage.

Biowatch

Biowatch 4分前

Everyone I’ve heard from says that shingles is miserable, so I’m getting my vaccinations.

Golden Cross

Golden Cross 5分前

$AABB Share Buyback Program: The Company began its share buyback program in the first quarter of 2025. Subject to various limitations and restrictions, the Company has purchased $11,312,000 of AABB common shares as of March 31, 2026. The Buy-Back Program is on-going.

https://investors

nathanial

nathanial 6分前

Not that I have heard yet during the past 8 years. Still holding.

learningcurve2020

learningcurve2020 7分前

LL just literally told you they still have no idea why it seems to work in some but not others, yet you claim they have a handle on it while they can’t even get another trial off the ground for adults or kids. Obviously the issue is cost and the nebulousness of the trial. NICE must require some kin

Golden Cross

Golden Cross 8分前

$AABB Share Buyback Program: The Company began its share buyback program in the first quarter of 2025. Subject to various limitations and restrictions, the Company has purchased $11,312,000 of AABB common shares as of March 31, 2026. The Buy-Back Program is on-going.

https://investors

vg_future

vg_future 11分前

Well said Lacey1...same BS spewing all over the place....yet again. It is the ASM that got scheduled to Sep 24th. 2026 with a shareholder record date of July 31st. There is no info or filing about the quarterly filing, but based on the various IR conversations by multiple people (I spoke to IR as w

FannieMan

FannieMan 11分前

Lol wonder which cult leader put those words in her mouth.

More distractions.

Eli-316

Eli-316 12分前

It's trading at .001 or rock bottom.
What is there to destroy?

Seminole Red

Seminole Red 13分前

Chevy teams will jump

Lightning_Rod

Lightning_Rod 14分前

Yes not lately.

There was Lots of chatter about the inclusion in the Russell index so June 2nd I made that post and personally felt there would be NO significant price appreciation.

Just for record.

L_R

Myth

Samantha Fish - Kick Out the Jams Live

https://www.youtube.com/watch?v=1BtWd8CCECg

Myth

The Rolling Stones - Paint It, Black

https://www.youtube.com/watch?v=765lOdIN940

Aquahoya

Aquahoya 19分前

Yeah. I am more Mental Health related but help researchers in every corner of the medical field. My biochemistry is very rusty so I would have to do some reading on it. All I read is the peptide is highly speculative and preclinical at the moment. Have to check the data and research papers. Probably

jimmybob

jimmybob 19分前

$FUBO current price: $9.91 (24% Short Interest) - every analyst has a PT 50%+ higher than here

Recent analyst ratings and PTs:

6/12: Needham Buy rating w/ $15 PT
6/11: Barrington Outperform w/ 16 PT
6/11: Citizens Outperform w/ $15 PT

eagle8

eagle8 19分前

t is very funny that an old acquaintance of the board, "poor man", shows up again every now and then, without any shame whatsoever.
I received a reaction to my post in the form of a smiling face from him.
Poor man, I had you on ignore for years before you disappeared from the board.

Genz2

Holy Smokes Methinks, have you checked out the prices of Palo Alto firewalls?? Have you looked at Palo Alto Networks’ complicated Idira?? You can’t figure out the pricing for that so the product must be really complicated too!!! Then Palo Alto’s firewalls have had all kinds of problems in the pas

walterc

walterc 23分前

I think market makers have been manipulating LWLG from 1 to 20 , back to 1 and then 18 and now to 8;
They create phantom shares when they want and there is no adequate control over it.
It are not the retail shareholders who made these moves.

It was not Ted

HammerTime 102

HammerTime 102 24分前

Specifically that the share price would be, or could be, crushed? And, while it was happening you pointed to the share price decline over the past week? Sorry. Again, more hot air, no real substance.

Lime Time

Lime Time 24分前

Annual filed. Good .0001 buy 🚀

In it

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。